Zobrazeno 21 - 30
of 90
pro vyhledávání: '"Toshiki Iwai"'
Autor:
Mieko Yanagisawa, Koh Furugaki, Kaname Yamamoto, Masamichi Sugimoto, Mitsue Kurasawa, Keigo Yorozu, Nobuyuki Ishikura, Chinami Masuda, Toshiki Iwai
Publikováno v:
International Journal of Oncology
Erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), shows superior efficacy in patients with non-small cell lung cancer (NSCLC) harboring activating EGFR mutations (EGFR Mut+). However, almost all tumors eventually
Autor:
Mariko Noguchi-Sasaki, Mitsue Kurasawa, Kaname Yamamoto, Masamichi Sugimoto, Keigo Yorozu, Nobuyuki Ishikura, Toshiki Iwai, Mieko Yanagisawa
Publikováno v:
Anticancer Research. 37:623-630
Background Bevacizumab in combination with chemotherapeutics has shown significant survival benefit in clinical studies in patients with non-small cell lung cancer (NSCLC). Since bevacizumab was administered as standard treatment until disease progre
Autor:
Sung-Won, Kim, Yoshitaka, Asakura, Kinuko, Tajima, Toshiki, Iwai, Hirofumi, Taji, Takaaki, Chou, Yasuo, Morishima, Junji, Suzumiya, Hisashi, Sakamaki, Ritsuro, Suzuki, Takahiro, Fukuda
Publikováno v:
International journal of hematology. 111(2)
To investigate the use of high-dose therapy and autologous stem cell transplantation (ASCT) for relapsed or high-risk diffuse large B-cell lymphoma (DLBCL) between 1990 and 2007, we conducted a nationwide survey using the registry database of the Jap
Autor:
Daisuke Mizutani, Taiji Sakai, Toshiki Iwai, Takayuki Inaba, Seiki Sakuyama, Kenji Iida, Yoshinori Miyazawa, Hidehiko Fujisaki, Akira Tamura
Publikováno v:
2019 IEEE 69th Electronic Components and Technology Conference (ECTC).
Silicon interposer (Si-IP) technology has been used in accelerated processing units such as graphic processing units in high-performance computing because it can package a system-on-chip and high bandwidth memories. However, the conventional Si-IP ha
Autor:
Yoshiaki Chinen, Ayako Muramatsu, Yuji Shimura, Hisao Nagoshi, Yoshiko Hirakawa, Masafumi Taniwaki, Junya Kuroda, Yosuke Matsumoto, Hitoji Uchiyama, Toshiki Iwai, Kodai Kuriyama, Shigeo Horiike, Muneo Ohshiro, Tomohiko Taki, Nana Sasaki
Publikováno v:
International journal of hematology. 111(1)
Expression of intragenic exon rearrangements (IERs) has reportedly been detected in both normal and cancer cells. However, there have been few reports of occurrence of these rearrangements specific to neoplasms including malignant lymphoma. In this s
Publikováno v:
Anticancer research. 39(4)
Background Immune checkpoint inhibitors have marked antitumor effect. However, monotherapy benefits only a limited population of patients, and further improvement of their effects is required. Here the therapeutic effect and immune response during an
Autor:
Daisuke Mizutani, Kenji Iida, Seiki Sakuyama, Akira Tamura, Takayuki Inaba, Yoshinori Miyazawa, Taiji Sakai, Hidehiko Fujisaki, Toshiki Iwai
Publikováno v:
2018 IEEE CPMT Symposium Japan (ICSJ).
High-density packaging technologies such as 2.5D interposer technology have the potential to enhance computing performance because interposer technologies can improve input/output connections for multi-chip packaging. However, it is difficult to use
Autor:
Takaaki Chou, Hisashi Sakamaki, Toshiki Iwai, Kinuko Tajima, Yasuo Morishima, Takahiro Fukuda, Hirofumi Taji, Junji Suzumiya, Ritsuro Suzuki, Sung-Won Kim, Yoshitaka Asakura
Publikováno v:
International Journal of Hematology. 112:907-907
To investigate the use of high-dose therapy and autologous stem cell transplantation (ASCT) for relapsed or high-risk diffuse large B-cell lymphoma (DLBCL) between 1990 and 2007, we conducted a nationwide survey using the registry database of the Jap
Autor:
Keigo Yorozu, Kaname Yamamoto, Suguru Harada, Mitsue Kurasawa, Toshiki Iwai, Masamichi Sugimoto
Publikováno v:
Oncology Reports
Vascular endothelial growth factor (VEGF)-neutralizing therapy with bevacizumab has become increasingly important for treating colorectal cancer. It was demonstrated that second-line chemotherapy together with bevacizumab after disease progression (P
Autor:
Junko Fukumura, Naoki Harada, Koh Furugaki, Kaname Yamamoto, Mitsue Kurasawa, Keigo Yorozu, Mieko Yanagisawa, Kenichi Suda, Yoichiro Moriya, Toshiki Iwai, Tetsuya Mitsudomi, Hiroshi Mizuuchi
Publikováno v:
International Journal of Cancer. 138:1024-1032
Erlotinib (ERL), an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, shows notable efficacy against non-small cell lung cancer (NSCLC) harboring EGFR mutations. Bevacizumab (BEV), a humanized monoclonal antibody to vascular endothel